GSK has invested $7.7 million in a new pilot vaccine facility with the hope Australian manufacturing innovation could reduce cost of vaccination in developing world.
Immunisation rates among Australian children has risen significantly over the years. However, there remains a distinct disparity between children from Aboriginal and Torres Strait Islander communities and other Australians.
Patients & consumers
New medicines are urgently needed for diseases of the developing world and those medicines need to be affordable.